Your browser doesn't support javascript.
loading
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Younes, Anas; Brody, Joshua; Carpio, Cecilia; Lopez-Guillermo, Armando; Ben-Yehuda, Dina; Ferhanoglu, Burhan; Nagler, Arnon; Ozcan, Muhit; Avivi, Irit; Bosch, Francesc; Caballero Barrigón, Maria Dolores; Hellmann, Andrzej; Kuss, Bryone; Ma, David D F; Demirkan, Fatih; Yagci, Münci; Horowitz, Netanel A; Marlton, Paula; Cordoba, Raul; Wrobel, Tomasz; Buglio, Daniela; Streit, Michael; Hodkinson, Brendan P; Schaffer, Michael; Alvarez, John; Ceulemans, Rob; Balasubramanian, Sriram; de Jong, Jan; Wang, Shean-Sheng; Fourneau, Nele; Jurczak, Wojciech.
Afiliação
  • Younes A; Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: younesa@mskcc.org.
  • Brody J; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Carpio C; University Hospital Vall d'Hebron, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Lopez-Guillermo A; Department of Hematology, Hospital Clínic, Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Barcelona, Spain.
  • Ben-Yehuda D; Hadassah Medical Center, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel.
  • Ferhanoglu B; Department of Hematology, Koç University School of Medicine, Istanbul, Turkey.
  • Nagler A; Chaim Sheba Medical Centre, Tel-Hashomer, Israel.
  • Ozcan M; Ankara University School of Medicine, Ankara, Turkey.
  • Avivi I; Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Bosch F; University Hospital Vall d'Hebron, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Caballero Barrigón MD; Hospital Clínico Universitario de Salamanca, Salamanca, Spain.
  • Hellmann A; Medical University of Gdansk, Gdansk, Poland.
  • Kuss B; Flinders Medical Centre and Flinders University, Adelaide, SA, Australia.
  • Ma DDF; St Vincent's Hospital, Sydney, NSW, Australia.
  • Demirkan F; Dokuz Eylül University, Izmir, Turkey.
  • Yagci M; Gazi University, Ankara, Turkey.
  • Horowitz NA; Rambam Health Care Campus, Haifa, Israel.
  • Marlton P; Princess Alexandra Hospital, University of Queensland School of Medicine, Brisbane, QLD, Australia.
  • Cordoba R; Fundacion Jimenez Diaz University Hospital, Madrid, Spain.
  • Wrobel T; Wroclaw Medical University, Wroclaw, Poland.
  • Buglio D; Bristol-Myers Squibb, Lawrenceville, NJ, USA.
  • Streit M; Janssen R&D, Spring House, PA, USA.
  • Hodkinson BP; Janssen R&D, Spring House, PA, USA.
  • Schaffer M; Janssen R&D, Spring House, PA, USA.
  • Alvarez J; Janssen R&D, Spring House, PA, USA.
  • Ceulemans R; Janssen R&D, Beerse, Belgium.
  • Balasubramanian S; Janssen R&D, San Diego, CA, USA.
  • de Jong J; Janssen R&D, San Diego, CA, USA.
  • Wang SS; Janssen R&D, Raritan, NJ, USA.
  • Fourneau N; Janssen R&D, Beerse, Belgium.
  • Jurczak W; Department of Hematology, Jagiellonian University, Krakow, Poland.
Lancet Haematol ; 6(2): e67-e78, 2019 Feb.
Article em En | MEDLINE | ID: mdl-30642819
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Segurança / Linfoma não Hodgkin / Leucemia Linfocítica Crônica de Células B / Nivolumabe Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Haematol Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Segurança / Linfoma não Hodgkin / Leucemia Linfocítica Crônica de Células B / Nivolumabe Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Haematol Ano de publicação: 2019 Tipo de documento: Article